18F-FET PET compared with18F-FDG PET and CT in patients with head and neck cancer

Journal of Nuclear Medicine

Volumn 47, Issue 2, 2006, Pages 256-261

  Pauleit, Dirk ^a,b,d   Zimmermann, Andre ^c   Stoffels, Gabriele ^a   Bauer, Dagmar ^a   Risse, Jörn ^b   Flüss, Michael O ^c   Hamacher, Kurt ^d   Coenen, Heinz H ^d   Langen, Karl Josef ^a  

^a Brain Imaging Center West   (Germany)

^b Radiology and Nuclear Medicine Institute   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

18F FDG; 18F FET; Amino acids; Head and neck cancer; PET; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROETHYLETHYLTYROSINE F 18; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; O (2 FLUOROETHYL)TYROSINE; O-(2-FLUOROETHYL)TYROSINE; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; CLINICAL TRIAL; COMPARATIVE STUDY; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TYROSINE;

EID: 33646021544     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics: 1996. CA Cancer J Clin. 1996;46:5-27.
2. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184-194.
3. Di Martino E, Rieger M, Hassan HA, et al. Multiple primary carcinomas in patients with head and neck malignancies. Laryngorhinootologie. 2000;79:711-718.
4. Hain SF. Positron emission tomography in cancer of the head and neck. Br J Oral Maxillofac Surg. 2005;43:1-6.
5. 18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior? Eur Arch Otorhinolaryngol. 2004;261:479-483.
6. 18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer. 2003;98:2257-2265.
7. McGuirt WF, Greven K, Williams D III, et al. PET scanning in head and neck oncology: a review. Head Neck. 1998;20:208-215.
8. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
9. Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck. 2001;23:1056-1060.
10. 18FDG PET. AJR. 2005;184:1326-1331.
11. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
12. Reinhardt MJ, Kubota K, Yamada S, et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 1997;38:280-287.
13. 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med. 2001;28:816-821.
14. 18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg. 2003;61:1022-1029.
15. Greven KM, Keyes JW Jr, Williams DW III, et al. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. 1999;86:114-118.
16. Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol. 2003;5:257-270.
17. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484-492.
18. de Boer JR, van der Laan BF, Pruim J, et al. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. Eur J Nucl Med Mol Imaging. 2002;29:1182-1187.
19. Lindholm P, Leskinen S, Lapela M. Carbon-11-methionine uptake in squamous cell head and neck cancer. J Nucl Med. 1998;39:1393-1397.
20. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
21. 18F]fluoroethyl)-L-tyrosine. Appl Radiat Isot. 2002;57:853-856.
22. Langen KJ, Jarosch M, Mühlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501-508.
23. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
24. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Mol Imaging. 2004;31:1464-1470.
25. 18F]fluoroethyl) -L-tyrosine PET combined with magnetic resonance imaging improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
26. 18F] fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318-327.
27. 18F] fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422-429.
28. Kaim AH, Weber B, Kurrer MO, et al. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging. 2002;29:648-654.
29. Rau FC, Weber WA, Wester HJ, et al. O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002;29:1039-1046.
30. 18F]fluoroethyl)-L-tyrosine (FET) in peripheral tumours: first clinical results. J Nucl Med. 2005;46:411-416.
31. Sobin LH, Wittekind C, eds. UICC-TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
32. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
33. Pietrzyk U, Herholz K, Heiss WD. Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr. 1990;14:51-59.
34. 125I-iodo-alpha-methyl-L-tyrosine membrane transport in human L-type amino acid transporters. J Nucl Med. 2003;44:244-246.
35. Lahoutte T, Caveliers V, Camargo SMR, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLat1) and its transstimulation. J Nucl Med. 2004;45:1591-1596.
36. Rau FC, Philippi H, Rubio-Aliaga I, et al. Identification of subtypes of amino acid transporters in human tumor and inflammatory cells by RT-PCR [abstract]. J Nucl Med. 2002;43(suppl):24P.
37. De Boer JR, Pruim J, Burlage F, et al. Therapy evaluation of laryngeal carcinomas by tyrosine-PET. Head Neck. 2003;25:634-644.
38. Braams JW, Pruim J, Nikkels PGJ, et al. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med. 1996;37:897-901.
39. Buus S, Grau C, Munk OL, et al. 11C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. Radiother Oncol. 2004;73:289-296.
40. Geets X, Daisne JF, Gregoire V, et al. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol. 2004;71:267-273.